Sanofi SA is looking at potential U.S. biotech acquisitions as it seeks to expand its work in multiple sclerosis and immune disorders, Bloomberg reports, citing unnamed sources.
–One of the targets being studied by the French company is Pricipia Biopharma Inc., Bloomberg reports.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.